COUNTY HALL | LONDON | 20 April, 2023
WHY ATTEND?
MEET decision makers at leading and upcoming drug discovery and technology companies from the UK and Nordic regions, and investment firms throughout Europe.
LEARN from major investment firms about the current status of European investment in life science technologies.
GAIN insights from experienced life science operators within the Anglo-Nordic space.
Anglonordic has a 20-year tradition as an invitation-only gathering of investors and R&D growth companies that consistently offers unique opportunities for funding and collaboration.
Become a part of Anglonordic 2023:
250+ Attendees
70+ Investor Firms
300+ Partnering Meetings
24 Startup Pitches
WHO WILL YOU MEET?
Exclusively selected attendees will represent the following key drivers of the European life sciences growth sector:
- CEOs, CSOs and Heads of Business Development from Emerging Life Science Companies in the Anglo-Nordic sphere and Continental Europe
- Decision-makers from Europe's key Investor firms and Pharma companies
- Key Supporters of the Life Science Ecosystem in Europe
Our 2022 event attracted an amazing total of 71 investment firms, with interests in a wide variety of technologies from small molecule discovery through protein technologies to AI applications and healthcare devices.
The following investment firms have already signed for Anglonordic 2023:
4BIO Capital, Apposite Capital, ATP, Axilium, Catalio Capital, Cell and Gene Therapy Catapult, Delin Ventures, Epidarex, Forbion, GGS Associates, GIMV, GL Investment, GSK, Hermes Partners Intl. Ltd., i2020 Accelerator, Illumina for Startups/Illumina Accelerator, Industrifonden, Kreos Capital, M Ventures, MIG Fonds, NG Bio Ltd, Norgine Ventures, Novo Holdings, o2h Ventures Ltd, Primavera Capital Group, Rosetta Capital, Ruffena Capital, Sound Bioventures, Start Codon, Sunstone Life Science Ventures, UCB Ventures